LDN, MCAS, and Why Individualized Dosing Matters
LDN, MCAS, and Why Individualized Dosing Matters
A Clinical Educator's Perspective on Low-Dose Naltrexone in Complex Immune-Mediated Illness
Yoon Hang Kim, MD, MPH
Introduction
Low-dose naltrexone (LDN) is frequently discussed as though a standard dose exists, a predictable response can be expected, and the path to clinical improvement is straightforward. In clinical practice—particularly among individuals living with mast cell activation syndrome (MCAS), dysautonomia, central sensitization, and post-viral immune dysregulation—the reality is considerably more nuanced.
The central teaching point of this article is deceptively simple: there is no universally "low" dose of LDN. The right dose is the dose that the individual client can tolerate and from which they can derive meaningful benefit.
The "Goldilocks Dose" Is Individual
Clients frequently ask, "What dose gave you a breakthrough?" when comparing notes with others who use LDN. While this curiosity is understandable, comparing doses between individuals can be profoundly misleading.
One person may tolerate several milligrams of LDN without difficulty. Another may develop significant symptoms at 0.25 mg. A highly sensitive individual may need to begin in the microgram range, and occasionally even lower amounts may warrant consideration.
Factors that may influence an individual's response include endorphin reserve, genetic polymorphisms, baseline immune state, exercise patterns, environmental exposures, concurrent illnesses, and overall neurobiological sensitivity [1, 2]. Given this complexity, a more clinically useful question than "What dose works for most people?" is:
What is the lowest dose this particular client can tolerate while moving toward therapeutic benefit?
"Low Dose" Is a Relative Term
Terminology in this space can generate unnecessary confusion—both for clinicians and for the individuals they serve. A brief orientation to scale may be helpful:
0.1 mg equals 100 micrograms. One microgram is one-millionth of a gram. One nanogram is one-billionth of a gram. One picogram is one-trillionth of a gram.
For a highly sensitive individual with MCAS or central sensitization, 0.25 mg may not feel "low" in any meaningful sense of the word. This is precisely why it is often clearer—and more clinically responsible—to state the actual dose numerically rather than relying on descriptors such as "low dose," "very low dose," or "ultra-low dose" [1].
Teaching pearl: State the number.
Side Effects Should Not Automatically Be "Powered Through"
A common misconception among clients—and occasionally among clinicians—is that an unpleasant reaction to LDN simply needs to be endured until the body adjusts. This is not always a sound strategy.
Symptoms reported in association with LDN may include insomnia, anxiety, headaches, dryness, gastrointestinal disturbance, skin changes, and other unexpected reactions [3, 4]. Whether a given reaction appears frequently in published literature is less clinically relevant than recognizing what is repeatedly happening to the individual sitting in front of you.
A reproducible symptom deserves clinical attention. Depending on the clinical situation, the prescribing clinician may consider stopping the medication entirely, reassessing the clinical picture, and potentially restarting at a substantially lower dose rather than making only an incremental dose reduction.
MCAS Clients Often Require a Fundamentally Different Strategy
Individuals with MCAS, dysautonomia, allodynia, central sensitization, and multiple medication sensitivities frequently react to doses that others tolerate without difficulty [5, 6, 7]. For these clients, the guiding principle is:
Start low. Go slow. Change one thing at a time.
This principle is particularly critical in MCAS because introducing multiple medications or supplements simultaneously can make it nearly impossible to determine what is producing benefit and what is triggering a reaction [8, 9]. Treating MCAS effectively is often less like a broad-spectrum approach and more like careful, deliberate sequencing—one intervention at a time, with adequate observation between changes.
Histamine Intolerance Should Raise the Question of MCAS
A client presenting with recurrent urticaria, rashes, food reactions, histamine intolerance, or multiple unexplained sensitivities may warrant formal evaluation for mast cell dysfunction [8, 10].
One important clinical challenge is that MCAS testing can produce false-negative results. A negative laboratory test therefore does not always resolve the clinical question—particularly when symptoms are episodic in nature and the timing of specimen collection may not coincide with a flare [10, 11].
The clinical approach that yields the most accurate picture integrates the full clinical history with laboratory findings, rather than allowing a single negative test result to close the diagnostic inquiry prematurely [11, 12].
LDN May Be Foundational Without Being Sufficient
LDN is a powerful immune-modulating tool, but it should not necessarily be treated as a stand-alone solution for complex immune-mediated illness [2, 13].
Some clients experience dramatic improvement with LDN alone. Others improve meaningfully only when LDN is combined thoughtfully with additional, complementary interventions. This concept can be described as therapeutic stacking—building a treatment strategy gradually, adding interventions when clinically appropriate, and carefully observing the response to each one before adding the next [9, 14].
For clients with MCAS or post-viral immune dysfunction, LDN may therefore function as a foundation rather than the entire therapeutic structure [9, 15].
If Something Stops Working, Investigate
Clients sometimes report that LDN worked extremely well for months or even years and then appeared to lose efficacy. This does not automatically mean that the medication has permanently failed.
The clinical picture may have shifted. Depending on the individual, a clinician might consider whether the dose needs adjustment, whether a new illness or immune trigger has emerged, whether medications or lifestyle factors have changed, or whether a treatment break or dosing strategy modification might be appropriate [1, 4].
The larger lesson is that chronic illness treatment is inherently dynamic. What worked yesterday may need to be reassessed tomorrow.
Medication Changes Should Be Coordinated, Not Impulsive
Individuals who have been chronically ill for years understandably become exhausted by the burden of medications, restrictions, and persistent symptoms. When they finally experience improvement, it can be tempting to discontinue other treatments rapidly.
But improvement is not automatically proof that every other medication has become unnecessary. In MCAS particularly, abruptly discontinuing antihistamines or other stabilizing therapies may destabilize a client who had previously been doing well [8, 9].
The therapeutic endpoint should not be defined simply as "fewer medications." The endpoint is meaningful, sustained improvement in the client's health and functional capacity.
The LDN–Opioid Interaction: A Critical Safety Consideration
Naltrexone interacts with opioid receptors. A client who requires an opioid for acute pain management—whether for a surgical procedure, an injury, or another clinical indication—may therefore need a modified LDN strategy, because LDN can interfere with the effectiveness of opioid medication [1, 16].
Depending on the clinical circumstances, the treating clinician may consider temporarily discontinuing LDN or implementing another carefully planned approach [16]. This is emphatically not an area suited for self-experimentation. It requires individualized medical supervision and clear communication between the client and their care team.
Synthesis: The Recurring Principles
LDN is not a one-size-fits-all medication. MCAS is not a one-size-fits-all illness. The principles that emerge consistently from clinical experience with these overlapping conditions can be summarized as follows:
Respect individual sensitivity. No two clients will respond identically, and clinical humility in the face of biological variability is not weakness—it is precision.
Use actual dose numbers rather than vague labels. Precision in language supports precision in care.
Start low and go slowly when the clinical situation warrants it. This is especially true in MCAS, central sensitization, and post-viral syndromes.
Do not dismiss reproducible symptoms. If a client reports the same reaction consistently, that finding deserves clinical weight regardless of whether it appears in a published side-effect profile.
Avoid changing multiple treatments simultaneously. When multiple variables change at once, the ability to attribute cause and effect is lost.
Think of LDN as one tool within a broader immune-modulation strategy. Foundational does not mean solitary.
And most importantly: treat the client in front of you rather than the theoretical "average" client.
Disclaimer: This article is for educational purposes and does not constitute individual medical advice. Medication initiation, discontinuation, dilution, and dose adjustments should always be discussed with an appropriately licensed clinician or compounding pharmacist.
References
LDN: Pharmacology, Mechanisms, and Clinical Evidence
1. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences. 2018;6(4):82. doi:10.3390/medsci6040082.
2. Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology. 2018;61:178–184. doi:10.1016/j.intimp.2018.06.004.
3. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x.
4. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism. 2013;65(2):529–538. doi:10.1002/art.37734.
5. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016.
6. Zapata N, Georgiadi E, Cantrell C, et al. Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia. Cureus. 2025;17(6):e86538. doi:10.7759/cureus.86538.
7. Bruun-Plesner K, Barkhuus C, Ekholm O, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia—effect via a central mechanism? A randomized, double-blinded, placebo-controlled, crossover study. ClinicalTrials.gov Identifier: NCT02806440. Completed 2022.
MCAS: Diagnosis, Pathophysiology, and Treatment
8. Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016;389(7):671–694. doi:10.1007/s00210-016-1247-1.
9. Kim YH. A functional medicine approach to mast cell activation syndrome (MCAS). IFM Synergy Blog. January 25, 2026. https://www.ifmsynergy.com/a-functional-medicine-approach-to-mast-cell-activation-syndrome-mcas/.
10. Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: Current understanding and research needs. Journal of Allergy and Clinical Immunology. 2024;154(2):255–263. doi:10.1016/j.jaci.2024.05.025.
11. Akin C. Dilemma of mast cell activation syndrome: Overdiagnosed or underdiagnosed? Journal of Allergy and Clinical Immunology: In Practice. 2024;12(3):762–763. doi:10.1016/j.jaip.2024.01.021.
12. Afrin LB, Blitshteyn S, Bluestein LS, et al. Progress in mast cell activation syndrome: The global consensus-2 diagnostic criteria at six years. Diagnosis (Berlin). 2026;published online June 4, 2026. doi:10.1515/dx-2026-0016.
LDN in Mast Cell Disorders
13. Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405.
14. Weinstock LB, Afrin LB. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research. 2025;16(5):134–135.
15. Kurta AO, Weinstock LB, Semchyshyn N. Erythromelalgia in a patient with mast cell activation syndrome: Response to low dose naltrexone. SKIN: The Journal of Cutaneous Medicine. 2020;4(3):268–270. doi:10.25251/skin.4.3.14.
Opioid–Naltrexone Interactions and Safety
16. Yaghoubi F, Vahed N, Bhatt S, Zamani A. Low-dose naltrexone co-treatment in the prevention of opioid-induced hyperalgesia. Cureus. 2021;13(10):e18735. doi:10.7759/cureus.18735.
Central Sensitization and Neuroinflammation
17. Pereira Santos AR, Buosi S, Kenji Nakamura L. Low-dose naltrexone in chronic pain management: Mechanisms, evidence, and clinical implications. Journal of Personalized Medicine. 2026;16(3):151. doi:10.3390/jpm16030151.
18. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Frontiers in Cellular Neuroscience. 2019;13:353. doi:10.3389/fncel.2019.00353.
Scoping Reviews and Meta-Analyses
19. Aref HMA, Moustafa AM, Khalil SH, et al. Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: A systematic review and meta-analysis. Frontiers in Medicine. 2025;12:1563479. doi:10.3389/fmed.2025.1563479.
20. Trofimovitch D, Bhatt SJ, Engel ER, et al. Therapeutic uses and efficacy of low-dose naltrexone: A scoping review. Biomedicines. 2025;13(4):938. doi:10.3390/biomedicines13040938.
About Dr. Kim
Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. He completed the University of Arizona/Andrew Weil Center for Integrative Medicine fellowship and holds board certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of three books and more than 20 peer-reviewed articles.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
